In primary samples of patients with IDH1/2mt AML treated with mtIDH1/2 inhibitors, resistance to mtIDH1/2 inhibitors was more frequently observed in patients with versus patients without a hypermethylated genotype with a gene expression profile associated with AML stemness. The gene discussed is IDH1; the disease is acute myeloid leukemia.